Imidazolyl ethanamide pentandioic acid is under clinical development by Myelo Therapeutics and currently in Phase II for Chemotherapy Induced Neutropenia. According to GlobalData, Phase II drugs for Chemotherapy Induced Neutropenia have a 77% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Imidazolyl ethanamide pentandioic acid’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Imidazolyl ethanamide pentandioic acid overview
Imidazolidinyl pentanedioic acid (Ingavirin) is a anti-viral agent. It is formulated as capsules for oral route of administration. Ingavirin is indicated for the treatment and prevention of influenza A, B and other acute viral respiratory infections in adults.
Myelo-001 is under development for the treatment of coronavirus disease 2019 (COVID-19), chemotherapy-induced neutropenia (CIN), chemotherapy-induced myelosuppression(CIM), radiation-induced myelosuppression (RIM) and acute radiation syndrome (ARS). It was also under development for hepatitis C, enterovirus infections, yellow fever and viral respiratory tract infection for pediatric patients under age group of 6 months to 2 years. The drug candidate is administered orally. It is imidazolyl ethanamide pentandioic acid which acts on hematogenesis. It was also under development for chemotherapy-induced thrombocytopenia (CIT).
Myelo Therapeutics overview
Myelo Therapeutics is a medical technology company that develops novel treatments in areas with unmet medical needs. The company develops conventional chemotherapeutic agents for use in anticancer treatments. It develops myelo001, a small molecule for the treatment of patients with chemotherapy-induced neutropenia and thrombocytopenia. Myelo Therapeutics offers myelo001 for both the protection of immature granulocytic cells in their early stage after cytostatic treatment and for the more active maturation of neutrophils. The company operates in Berlin and Dresden. Germany. Myelo Therapeutics is headquartered in Berlin, Germany.
For a complete picture of Imidazolyl ethanamide pentandioic acid’s drug-specific PTSR and LoA scores, buy the report here.